Trial Profile

A Phase I Study to Evaluate Safety and Early Signs of Efficacy of the Human Monoclonal Antibody-cytokine Fusion Protein IL12-L19L19

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dodekin (Primary)
Indications Carcinoma; Diffuse large B cell lymphoma; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions
Acronyms DODEKA
Sponsors Philogen

Most Recent Events

05 Apr 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.
05 Apr 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2025.
28 Feb 2024 Results (As of the cutoff date 30.10.2023, n=20) assessing safety of IL12-L19L19 in patients with solid tumors presented at the ESMO Targeted Anticancer Therapies Congress 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com